TORONTO, ON – Citagenix Inc., a subsidiary of Antibe Therapeutics, has launched PentOS OI™ Max for the dental biologics market.
PentOS OI™ Max is the newest member of the company’s PentOS OI™ family of bone grafts for oral and maxillofacial surgery. It is an inductive collagen matrix that can be mixed with the clinician’s choice of patient derived concentrates (including stem cells and blood components).
According to Antibe, osteoinductivity has been demonstrated in each lot in both in vivo and in vitro assays using independent laboratories. The company said that in vitro testing demonstrated levels of bone morphogenetic protein (BMP), a naturally occurring growth factor found in the human body that plays a crucial role in bone formation, of up to 40-times that of the control. Additionally, in vivo testing demonstrated all five elements of bone formation were present in PentOS OI™ grafts: chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone. The in vitro studies also demonstrated excellent cell viability and proliferation.
“Citagenix continues to augment its portfolio with the addition of high-quality products that support optimal patient outcomes at a competitive price point,” said Dan Legault, Antibe’s CEO. “Being the ‘portfolio-of-choice’ for dentists and oromaxillofacial surgeons is important to our global growth strategy and is supported by an active business development funnel.”
PentOS OI™ Max will be offered in the Canadian market through the company’s direct sales force and globally via its network of distribution partners.